fashion -WSS

fashion

author：explore 2025-10-03 00:40:51 - browse：2

Amylyx founders — Justin Klee, left, and Joshua Cohen, both co-founders and co-CEO's of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neurodegenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

The filing will be based largely on a single clinical trial of AMX0035 completed one year ago that showed a significant slowing of disease progression in patients with ALS. It’s the same study that FDA officials told Amylyx last April was encouraging, but not convincing enough to review for approval on its own. The company was told by FDA staff to conduct another study, gather more positive data, and then file for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： A new drug could help frostbite victims avoid its ravages

WSS

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Amylyx ALS drug failure raises questions and concerns

The problem with charging patients to message their doctors

A new drug could help frostbite victims avoid its ravages

New study raises questions about niacin and heart health

Weight loss drugs aren’t covered by Obamacare. That may change

focus

fashion

Wikipedia

How one medical school became remarkably diverse

Precocious puberty in girls comes with mental health risks

23andMe had bad news about my health. I wish a person had delivered it

The problem with charging patients to message their doctors

Alkermes shareholders re

In his State of the Union, Biden takes clear aim at 'Big Pharma'

What does generative AI mean for health care? We asked experts

Measles policy set amid Florida outbreak alarms vaccine proponents

After affirmative action ruling, medical educators look to 'holistic review'

NEJM study link tiny plastics in blood vessels to heart problems

knowledge

With psoriasis trial ahead, Alumis raises $259 million

Amylyx ALS drug failure raises questions and concerns

In his State of the Union, Biden takes clear aim at 'Big Pharma'

FDA warns medical device makers about rise in fabricated data

IVF, abortion rights issues kick off Biden’s State of the Union

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

explore

explore

hotspot

focus